

**Ventripoint**  
Diagnostics Ltd.

## Ultrasound AI for Cardiac Imaging

A Better Way to Analyze the Whole Heart

***OTC: VPTDF & TSX-V: VPT***


# Safe Harbour Statement

The information in this presentation may include forward-looking statements related to our future growth, trends in our industry, our financial and or operational results, and our financial or operational performance. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forward-looking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as "believes", "expects", "anticipates", "estimates", "intends", "plans", or similar expressions, or may employ such future or conditional verbs as "may", "will", "should" or "would", or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For these statements, we claim the protection of the safe harbour for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. The risks and uncertainties referred to above include, but are not limited to: variability of operating results among periods; inability to retain or grow our business due to execution problems resulting from significant headcount reductions, plant closures and product transfer associated with major restructuring activities; the effects of price competition and other business and competitive factors generally affecting the EMS industry; the challenges of effectively managing our operations during uncertain economic conditions; our dependence on a limited number of customers; our dependence on industries affected by rapid technological change; the challenge of responding to lower-than-expected customer demand; our ability to successfully manage our international operations; and delays in the delivery and/or general availability of various components used in the manufacturing process. These and other risks and uncertainties and factors are discussed in the Company's various public filings at [www.sedar.com](http://www.sedar.com) and [www.sec.gov](http://www.sec.gov), including our Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission. Except as required by applicable law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


# Capital Structure

Symbol: TSX-V: VPT & OTC: VPTDF

Shares Outstanding	90M
Shares Fully Diluted	128M
Recent share price	C\$0.08
52-Week Range	C\$0.07-\$0.15
Market Cap	C\$7M
Liquidity (90 days)	100M shares



# Highlights for 2020



- Major upgrades to improve ease of use, ease of installation and reduced cost
- Two purchase options: Buy or Lease  
Both have recurring revenue
- VMS+3.0 installed in 10 sites in 4 major markets
- Leading hospitals in cancer, paediatric CHD, adult CHD/PH, adult HF

# Key Recent Placements

MD Anderson Cancer Center  
Houston, TX – October 2020



Erasmus-Sophia University Medical Center  
The Netherlands - September 2020



Peter Munk  
Cardiac Centre-  
UHN  
Toronto,  
Canada -  
November  
2020

# Market Opportunity

Ventripoint has identified key market segments to drive sales



- **Congenital Heart Defects (CHD)**

- Standard-of-care guidelines require patient follow-up every three months for life

- **Pulmonary Hypertension (PAH)**

- Significant patient population

- **Cardiotoxic Effects of Chemotherapy**

- 20 – 30% of oncology patients experience heart damage

- **COVID-19 Patients**

- Virus causes heart damage in a high percentage of patients

\* In each case, Ventripoint can provide clinically important data faster and at less expense than MRI

# The Solution

## Ventripoint VMS+ 3.0 System

Processes all standard 2D echocardiograms to generate MRI equivalent 3D cardiac metrics


provides Cardiologists  
confidence in their diagnosis



Interfaces with all  
standard echocardiogram  
2D cardiac ultrasound  
machines (GE, Siemens,  
Philips, Toshiba)

10 year \$30M development  
of 3<sup>rd</sup> generation AI  
software has now elevated  
2D echocardiogram to MRI  
level accuracy

# Highlights for 2021



- Entering growth phase with goal to place 80-100 units by mid-2022
- Host Regional Ventripoint-moderated webinars featuring KOLs with VMS+3.0 experience. Two webinars planned in 1Q21 – one each for North America and Europe
- Key Opinion Leaders (KOL) per market segment to present/publish at major medical conferences
- Publish case studies and institutional experiences of major heart centres using VMS+3.0




# Key Investment Considerations



- \$2B+ market opportunity
- Substantially de-risked – product is developed, regulatory approvals in hand and sales successfully under way
- Recent acquisitions suggest valuations of >\$100M very feasible
- Proven team has accomplished similar plans multiple times in the past
- Current valuation of ~\$6M enables excellent return

# Thank You



**OTC: VPTDF & TSX-V: VPT**

For further information contact:

Dr. George Adams – CEO

[gadams@ventripoint.com](mailto:gadams@ventripoint.com)

**Ventripoint Diagnostics Ltd.**

2 Sheppard Avenue East, Suite 605

Toronto Ontario M2N 5Y7 Canada

(416)-848-4156

Investor Relations:

Clay Chase @ Torrey Hills Capital

(858) 456-7300

[cc@sdthc.com](mailto:cc@sdthc.com)

Website: [www.ventripoint.com](http://www.ventripoint.com)